

1. [Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.](#)  
Fokas E, Fietkau R, Hartmann A, Hohenberger W, Grützmann R, Ghadimi M, Liersch T, Ströbel P, Grabenbauer GG, Graeven U, Hofheinz RD, Köhne CH, Wittekind C, Sauer R, Kaufmann M, Hothorn T, Rödel C; German Rectal Cancer Study Group.  
Ann Oncol. 2018 Jul 1;29(7):1521-1527. doi: 10.1093/annonc/mdy143.  
PMID: 29718095 [PubMed - in process]  
-----
2. [Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review.](#)  
Goey KKH, Mahmoud R, Sørbye H, Glimelius B, Köhne CH, Sargent DJ, Punt CJA, van Oijen MGH, Koopman M.  
Eur J Cancer. 2018 Jun;96:115-124. doi: 10.1016/j.ejca.2018.03.026. Epub 2018 May 2. Review.  
PMID: 29729562 [PubMed - in process]  
-----
3. [Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.](#)  
Siena S, Rivera F, Taieb J, Peeters M, Prenen H, Koukakis R, Demonty G, Köhne CH.  
Clin Colorectal Cancer. 2018 Mar;17(1):50-57.e8. doi: 10.1016/j.clcc.2017.09.006. Epub 2017 Sep 28.  
PMID: 29096990 [PubMed - in process] **Free Article**  
-----
4. [BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.](#)  
van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, Solbach C, Köhne CH, Thomssen C, Forstbauer H, Hoffmann G, Kohls A, Schmatloch S, Schem C, von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S, Marmé F.  
Breast Cancer Res Treat. 2017 Dec;166(3):775-785. doi: 10.1007/s10549-017-4444-9. Epub 2017 Aug 18.  
PMID: 28822007  
-----
5. [Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in Hereditary Hemorrhagic Telangiectasia.](#)  
Chavan A, Schumann-Binarsch S, Schmuck B, Oltmer F, Geisthoff U, Hoppe F, Wirsching K, Klempnauer J, Manns M, Philip Thomas R, Köhne CH.  
Am J Hematol. 2017 Nov;92(11):E641-E644. doi: 10.1002/ajh.24878. Epub 2017 Aug 24. No abstract available.  
PMID: 28776732  
-----
6. [Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.](#)  
Wattad M, Weber D, Döhner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, Thol F, Kindler T, Lübbert M, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Köhne CH, Ringhoffer M, Wulf G, Held G, Salwender H, Benner A, Ganser A, Döhner H, Schlenk RF.  
Leukemia. 2017 Jun;31(6):1306-1313. doi: 10.1038/leu.2017.23. Epub 2017 Jan 19.  
PMID: 28138160  
-----
7. [Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.](#)  
Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR, Held G, Köhne CH, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst HA, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk RF.  
Blood Cancer J. 2017 May 26;7(5):e564. doi: 10.1038/bcj.2017.45.  
PMID: 28548643 **Free PMC Article**

- 
8. [Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t\(8;21\)\(q22;q22\): a study of the German-Austrian AML Study Group.](#)  
Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik VI, Schmalbrock L, Thol F, Heuser M, Krauter J, Göhring G, Kündgen A, Fiedler W, Wattad M, Held G, Köhne CH, Horst HA, Lübbert M, Ganser A, Schlenk RF, Döhner H, Döhner K, Paschka P.  
Leukemia. 2017 Apr;31(4):1012-1015. doi: 10.1038/leu.2017.18. Epub 2017 Jan 16. No abstract available.  
PMID: 28090090
  - 
  9. [Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.](#)  
Gerullis H, Wawroschek F, Köhne CH, Ecke TH.  
Ther Adv Urol. 2017 Jan;9(1):28-35. doi: 10.1177/1756287216677903. Epub 2016 Nov 21. Review.  
PMID: 28042310 [PubMed] **Free PMC Article**
  - 
  10. [All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.](#)  
Schlenk RF, Lübbert M, Benner A, Lamparter A, Krauter J, Herr W, Martin H, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Wattad M, Köhne CH, Fiedler W, Bentz M, Wulf G, Held G, Hertenstein B, Salwender H, Gaidzik VI, Schlegelberger B, Weber D, Döhner K, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group.  
Ann Hematol. 2016 Dec;95(12):1931-1942. Epub 2016 Oct 3.  
PMID: 27696203 **Free PMC Article**
  - 
  11. [Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.](#)  
Karthaus M, Hofheinz RD, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Oliner KS, Boedigheimer M, Twomey B, Zhang Y, Demonty G, Köhne CH.  
Br J Cancer. 2016 Nov 8;115(10):1215-1222. doi: 10.1038/bjc.2016.343. Epub 2016 Oct 20.  
PMID: 27764839 **Free PMC Article**
  - 
  12. [RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.](#)  
Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk RF, Döhner K, Döhner H.  
Leukemia. 2016 Nov;30(11):2282. doi: 10.1038/leu.2016.207. No abstract available.  
PMID: 27804971 [PubMed]
  - 
  13. [Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.](#)  
Theis F, Corbacioglu A, Gaidzik VI, Paschka P, Weber D, Bullinger L, Heuser M, Ganser A, Thol F, Schlegelberger B, Göhring G, Köhne CH, Germing U, Brossart P, Horst HA, Haase D, Götze K, Ringhoffer M, Fiedler W, Nachbaur D, Kindler T, Held G, Lübbert M, Wattad M, Salih HR, Krauter J, Döhner H, Schlenk RF, Döhner K.  
Leukemia. 2016 Nov;30(11):2248-2250. doi: 10.1038/leu.2016.185. Epub 2016 Jul 4. No abstract available.  
PMID: 27375010
  - 
  14. [RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.](#)  
Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA, Thol F, Heuser M, Schlegelberger B,

Ganser A, Bullinger L, Schlenk RF, Döhner K, Döhner H.

Leukemia. 2016 Nov;30(11):2160-2168. doi: 10.1038/leu.2016.126. Epub 2016 May 3. Erratum in: [Leukemia. 2016 Nov;30\(11\):2282.](#)

PMID: 27137476

-----

15. [FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.](#)

Köhne CH, Poston G, Folprecht G, Ciardiello F, Ronga P, Beier F, Van Cutsem E.

Eur J Surg Oncol. 2016 Oct;42(10):1540-7. doi: 10.1016/j.ejso.2016.05.038. Epub 2016 Jun 23.

PMID: 27575968

-----

16. [ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.](#)

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

PMID: 27843641 [PubMed] [Free PMC Article](#)

-----

17. [ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.](#)

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D.

Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.

PMID: 27380959

-----

18. [Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.](#)

Hütter-Krönke ML, Benner A, Döhner K, Krauter J, Weber D, Moessner M, Köhne CH, Horst HA, Schmidt-Wolf IG, Rummel M, Götze K, Koller E, Petzer AL, Salwender H, Fiedler W, Kirchen H, Haase D, Kremers S, Theobald M, Matzdorff AC, Ganser A, Döhner H, Schlenk RF.

Haematologica. 2016 Jul;101(7):839-45. doi: 10.3324/haematol.2015.141622. Epub 2016 Apr 1.

PMID: 27036160 [Free PMC Article](#)

-----

19. [Drug-drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacists.](#)

Gelderblom H, Köhne CH, Launay-Vacher V, van Leeuwen RW.

Ann Oncol. 2016 Apr;27(4):752. doi: 10.1093/annonc/mdw019. Epub 2016 Jan 19. No abstract available.

PMID: 26787233

-----

20. [Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.](#)

Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, Göhring G,

Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, Hänel M, Köhne CH, Lindemann HW, Berdel WE, Staib P, Müller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Brümmendorf TH, Edinger M, Hofmann WK, Pfirrmann M, Hasford J, Krause S, Hochhaus A, Sauße S, Hehlmann R; SAKK and the German CML Study Group.

Ann Hematol. 2015 Dec;94(12):2015-24. doi: 10.1007/s00277-015-2494-9. Epub 2015 Sep 18. PMID: 26385387

-----

21. [Is Progression-Free Survival the Right End Point in Trials of Patients With Clearly Resectable, Borderline Resectable, and Unresectable Liver-Limited Colorectal Cancer?](#)

Köhne CH.

J Clin Oncol. 2015 Jul 20;33(21):2406-7. doi: 10.1200/JCO.2014.60.7044. Epub 2015 Jun 1. No abstract available.

PMID: 26033812

-----

22. [FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.](#)

Bokemeyer C, Köhne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH, Tejpar S.

Eur J Cancer. 2015 Jul;51(10):1243-52. doi: 10.1016/j.ejca.2015.04.007. Epub 2015 Apr 30.

PMID: 25937522

-----

23. [Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.](#)

Argilés G, Saunders MP, Rivera F, Sobrero A, Benson A 3rd, Guillén Ponce C, Cascinu S, Van Cutsem E, Macpherson IR, Strumberg D, Köhne CH, Zalberg J, Wagner A, Luigi Garosi V, Grunert J, Tabernero J, Ciardiello F.

Eur J Cancer. 2015 May;51(8):942-9. doi: 10.1016/j.ejca.2015.02.013. Epub 2015 Mar 25.

PMID: 25818084

-----

24. [Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology \(SIOG\) consensus recommendations 2013.](#)

Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, Köhne CH, Rostoft S, Lemmens V, Mitry E, Rutten H, Sargent D, Sastre J, Seymour M, Starling N, Van Cutsem E, Apro M.

Ann Oncol. 2015 Mar;26(3):463-76. doi: 10.1093/annonc/mdu253. Epub 2014 Jul 11. Review.

PMID: 25015334

-----

25. [ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.](#)

Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne CH, Brossart P, Held G, Horst HA, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K.

Haematologica. 2015 Mar;100(3):324-30. doi: 10.3324/haematol.2014.114157. Epub 2015 Jan 16.

PMID: 25596267 **Free PMC Article**

-----

26. [Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.](#)

Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F.

J Clin Oncol. 2015 Mar 1;33(7):692-700. doi: 10.1200/JCO.2014.59.4812. Epub 2015 Jan 20.

PMID: 25605843

-----

27. [Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement.](#)

Yalcin S, Trad D, Kader YA, Halawani H, Demir OG, Mall R, Meshcheryakov A, Nasr F, Nosworthy A, Osinsky D, Tumanova A, Turhal S, Tejpar S, Köhne CH.

Future Oncol. 2014 Dec;10(16):2643-57. doi: 10.2217/fon.14.203. Review.

PMID: 25531050 **Free Article**

-----

28. [Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.](#)

Cheng AL, Li J, Vaid AK, Ma BB, Teh C, Ahn JB, Bello M, Charoentum C, Chen LT, de Lima Lopes G Jr, Ho GF, Kong HL, Lam KO, Liu TS, Park YS, Sriuranpong V, Sudoyo AW, Wang JY, Zhang J, Zhang SZ, Ciardiello F, Köhne CH, Shaw M, Kim TW.

Clin Colorectal Cancer. 2014 Sep;13(3):145-55. doi: 10.1016/j.clcc.2014.06.004. Epub 2014 Jun 26.

PMID: 25209093

-----

29. [Profiles of activation, differentiation-markers, or  \$\beta\$ -integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells.](#)

Vogt V, Schick J, Ansprenger C, Braeu M, Kroell T, Kraemer D, Köhne CH, Hausmann A, Buhmann R, Tischer J, Schmetzer H.

J Immunother. 2014 Jul-Aug;37(6):331-47. doi: 10.1097/CJI.0000000000000037.

PMID: 24911794

-----

30. [Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.](#)

Tassara M, Döhner K, Brossart P, Held G, Götze K, Horst HA, Ringhoffer M, Köhne CH, Kremers S, Raghavachar A, Wulf G, Kirchen H, Nachbaur D, Derigs HG, Wattad M, Koller E, Brugger W, Matzdorf A, Greil R, Heil G, Paschka P, Gaidzik VI, Göttlicher M, Döhner H, Schlenk RF.

Blood. 2014 Jun 26;123(26):4027-36. doi: 10.1182/blood-2013-12-546283. Epub 2014 May 5. Erratum in: Blood. 2015 May 7;125(19):3037.

PMID: 24797300 **Free Article**

-----

31. [Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.](#)

Metzner B, Müller TH, Gebauer W, Casper J, Kraemer D, Rosien B, Schumann-Binarsch S, Thole R, Köhne CH, Dreyling M, Hoster E, Pott C.

Ann Hematol. 2014 May;93(5):803-10. doi: 10.1007/s00277-013-1976-x. Epub 2013 Dec 13.

PMID: 24337447

-----

32. [Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept \(CELIM study\).](#)

Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH.

Ann Oncol. 2014 May;25(5):1018-25. doi: 10.1093/annonc/mdu088. Epub 2014 Feb 27.

PMID: 24585720

-----

33. [An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients.](#)

Regierer AC, Wolters R, Ufen MP, Weigel A, Novopashenny I, Köhne CH, Samonigg H, Eucker J, Possinger K, Wischneswsky MB.

Ann Oncol. 2014 Mar;25(3):633-8. doi: 10.1093/annonc/mdt539. Epub 2013 Dec 23.

PMID: 24368402 **Free PMC Article**

-----

34. [Metastatic breast cancer: are we treating the same patients as in the past?](#)

Ufen MP, Köhne CH, Wischneswsky M, Wolters R, Novopashenny I, Fischer J, Constantinidou M, Possinger K, Regierer AC.

Ann Oncol. 2014 Jan;25(1):95-100. doi: 10.1093/annonc/mdt429. Epub 2013 Nov 24.  
PMID: 24276026

-----

35. [Successes and limitations of targeted cancer therapy in colon cancer.](#)

Köhne CH.

Prog Tumor Res. 2014;41:36-50. doi: 10.1159/000356436. Epub 2014 Feb 17. Review.

PMID: 24727985

-----

36. [Pazopanib versus sunitinib in renal cancer.](#)

Casper J, Schumann-Binarsch S, Köhne CH.

N Engl J Med. 2013 Nov 14;369(20):1969. doi: 10.1056/NEJMc1311795. No abstract available.

PMID: 24224638

-----

37. [2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer \(HERA\): an open-label, randomised controlled trial.](#)

Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J; Herceptin Adjuvant (HERA) Trial Study Team.

Lancet. 2013 Sep 21;382(9897):1021-8. doi: 10.1016/S0140-6736(13)61094-6. Epub 2013 Jul 18.

PMID: 23871490

-----

38. [Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.](#)

Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J, Krauss J, Fischer R, Hamann S, Strumberg D, Mross KB.

Ann Oncol. 2013 Jun;24(6):1560-7. doi: 10.1093/annonc/mdt056. Epub 2013 Mar 13.

PMID: 23493136 **Free PMC Article**

-----

39. [Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation.](#)

Metzner B, Pott C, Müller TH, Gebauer W, Casper J, Kraemer D, Rosien B, Schumann-Binarsch S, Thole R, Köhne CH.

Ann Oncol. 2013 Jun;24(6):1609-15. doi: 10.1093/annonc/mds657. Epub 2013 Feb 7.

PMID: 23393125

-----

40. [Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil \(modified FOLFOX6\) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.](#)

Tabernero J, Garcia-Carbonero R, Cassidy J, Sobrero A, Van Cutsem E, Köhne CH, Tejpar S, Gladkov O, Davidenko I, Salazar R, Vladimirova L, Cheporov S, Burdaeva O, Rivera F, Samuel L, Bulavina I, Potter V, Chang YL, Lokker NA, O'Dwyer PJ.

Clin Cancer Res. 2013 May 1;19(9):2541-50. doi: 10.1158/1078-0432.CCR-13-0107. Epub 2013 Mar 26.

PMID: 23532888 **Free Article**

-----

41. [A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.](#)

Köhne CH, Bedenne L, Carrato A, Bouché O, Popov I, Gaspà L, Valladares M, Rougier P, Gog C, Reichardt P, Wils J, Pignatti F, Biertz F.

Eur J Cancer. 2013 May;49(8):1868-75. doi: 10.1016/j.ejca.2013.01.030. Epub 2013 Apr 6.

PMID: 23571150

-----

42. [Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations.](#)  
Schick J, Vogt V, Zerwes M, Kroell T, Kraemer D, Köhne CH, Hausmann A, Buhmann R, Tischer J, Schmetzer H.  
J Immunother. 2013 May;36(4):223-37. doi: 10.1097/CJI.0b013e31829180e7.  
PMID: 23603857  
-----
43. [Secondary genetic lesions in acute myeloid leukemia with inv\(16\) or t\(16;16\): a study of the German-Austrian AML Study Group \(AMLSG\).](#)  
Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Späth D, Kayser S, Schlegelberger B, Krauter J, Ganser A, Köhne CH, Held G, von Lilienfeld-Toal M, Kirchen H, Rummel M, Götze K, Horst HA, Ringhoffer M, Lübbert M, Wattad M, Salih HR, Kündgen A, Döhner H, Döhner K.  
Blood. 2013 Jan 3;121(1):170-7. doi: 10.1182/blood-2012-05-431486. Epub 2012 Oct 31.  
PMID: 23115274 **Free Article**  
-----
44. [Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients.](#)  
Ediebah DE, Coens C, Maringwa JT, Quinten C, Zikos E, Ringash J, King M, Gotay C, Flechtner HH, Schmucker von Koch J, Weis J, Smit EF, Köhne CH, Bottomley A; Gastro-Intestinal Tract Cancer Cooperative Group; Lung Cancer Cooperative Group; Quality of Life Department and Patient Reported Outcome and Behavioural Evidence (PROBE).  
Ann Oncol. 2013 Jan;24(1):231-7. doi: 10.1093/annonc/mds220. Epub 2012 Aug 30.  
PMID: 22935549 **Free PMC Article**  
-----
45. [Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.](#)  
Láng I, Köhne CH, Folprecht G, Rougier P, Curran D, Hitre E, Sartorius U, Griebisch I, Van Cutsem E.  
Eur J Cancer. 2013 Jan;49(2):439-48. doi: 10.1016/j.ejca.2012.08.023. Epub 2012 Oct 29.  
PMID: 23116683 **Free Article**  
-----
46. [ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.](#)  
Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Taberero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A.  
Ann Oncol. 2012 Oct;23(10):2479-516.  
PMID: 23012255  
-----
47. [Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.](#)  
Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E, Gamelin E, Baños A, Köhne CH.  
BMC Cancer. 2012 Sep 29;12:438. doi: 10.1186/1471-2407-12-438.  
PMID: 23020584 **Free PMC Article**  
-----
48. [Current stages of adjuvant treatment of colon cancer.](#)  
Köhne CH.  
Ann Oncol. 2012 Sep;23 Suppl 10:x71-6. No abstract available.  
PMID: 22987996  
-----

49. [Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.](#)  
Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne CH.  
Eur J Cancer. 2012 Jul;48(10):1466-75. doi: 10.1016/j.ejca.2012.02.057. Epub 2012 Mar 23.  
PMID: 22446022  
-----
50. [The gefitinib long-term responder \(LTR\)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program \(EAP\).](#)  
Gottschling S, Herpel E, Eberhardt WE, Heigener DF, Fischer JR, Köhne CH, Kortsik C, Kuhnt T, Muley T, Meister M, Bischoff HG, Klein P, Moldenhauer I, Schnabel PA, Thomas M, Penzel R.  
Lung Cancer. 2012 Jul;77(1):183-91. doi: 10.1016/j.lungcan.2012.03.003. Epub 2012 Apr 7.  
PMID: 22483783  
-----
51. [TET2 mutations in acute myeloid leukemia \(AML\): results from a comprehensive genetic and clinical analysis of the AML study group.](#)  
Gaidzik VI, Paschka P, Späth D, Habdank M, Köhne CH, Germing U, von Lilienfeld-Toal M, Held G, Horst HA, Haase D, Bentz M, Götze K, Döhner H, Schlenk RF, Bullinger L, Döhner K.  
J Clin Oncol. 2012 Apr 20;30(12):1350-7. doi: 10.1200/JCO.2011.39.2886. Epub 2012 Mar 19.  
PMID: 22430270  
-----
52. [Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma.](#)  
Peeters M, Cohn A, Köhne CH, Douillard JY.  
Clin Colorectal Cancer. 2012 Mar;11(1):14-23. doi: 10.1016/j.clcc.2011.06.010. Epub 2011 Sep 16. Review.  
PMID: 21925954  
-----
53. [Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies.](#)  
Kayser S, Zucknick M, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Rummel M, Germing U, Götze K, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Teleanu V, Ganser A, Döhner H, Schlenk RF; German-Austrian AML Study Group.  
Blood. 2012 Jan 12;119(2):551-8. doi: 10.1182/blood-2011-07-367508. Epub 2011 Nov 16.  
PMID: 22096250 **Free Article**  
-----
54. [First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.](#)  
Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M.  
J Cancer Res Clin Oncol. 2012 Jan;138(1):65-72. doi: 10.1007/s00432-011-1061-6. Epub 2011 Sep 30.  
PMID: 21960318  
-----
55. [Expression and prognostic value of FAS receptor/FAS ligand and TrailR1/TrailR2 in acute myeloid leukemia.](#)  
Pordzik S, Petrovici K, Schmid C, Kroell T, Schweiger C, Köhne CH, Schmetzer H.  
Hematology. 2011 Nov;16(6):341-50. doi: 10.1179/102453311X13127324303353.  
PMID: 22183068  
-----
56. [Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.](#)



Blanke CD, Bot BM, Thomas DM, Bleyer A, Kohne CH, Seymour MT, de Gramont A, Goldberg RM, Sargent DJ.

J Clin Oncol. 2011 Jul 10;29(20):2781-6. doi: 10.1200/JCO.2010.33.5281. Epub 2011 Jun 6.

PMID: 21646604 **Free PMC Article**

-----

57. [Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.](#)

Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zube A, Celik I, Rougier P, Ciardiello F.

J Clin Oncol. 2011 May 20;29(15):2011-9. doi: 10.1200/JCO.2010.33.5091. Epub 2011 Apr 18.

PMID: 21502544

-----

58. [Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.](#)

Van Cutsem E, Bajetta E, Valle J, Köhne CH, Hecht JR, Moore M, Germond C, Berg W, Chen BL, Jalava T, Lebowitz D, Meinhardt G, Laurent D, Lin E.

J Clin Oncol. 2011 May 20;29(15):2004-10. doi: 10.1200/JCO.2010.29.5436. Epub 2011 Apr 4.

PMID: 21464401

-----

59. [Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.](#)

Asseburg C, Frank M, Köhne CH, Hartmann JT, Griebisch I, Mohr A, Osowski U, Schulten J, Mittendorf T.

Clin Ther. 2011 Apr;33(4):482-97. doi: 10.1016/j.clinthera.2011.04.010.

PMID: 21635994

-----

60. [The impact of therapy-related acute myeloid leukemia \(AML\) on outcome in 2853 adult patients with newly diagnosed AML.](#)

Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kündgen A, Götze K, Rummel M, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Zucknick M, Ganser A, Döhner H, Schlenk RF; German-Austrian AMLSG.

Blood. 2011 Feb 17;117(7):2137-45. doi: 10.1182/blood-2010-08-301713. Epub 2010 Dec 2.

PMID: 21127174 **Free Article**

-----

61. [Long-term remissions in metastatic malignant melanoma following chemotherapy and tamoxifen maintenance.](#)

Metzner B, Casper J, Hartung G, Rosien B, Hölzle E, Pelzer P, Köhne CH.

Onkologie. 2011;34(4):208-9. doi: 10.1159/000327003. Epub 2011 Mar 18. No abstract available.

PMID: 21447982 **Free Article**

-----

62. [How to integrate molecular targeted agents in the continuum of care.](#)

Köhne CH.

Ann Oncol. 2010 Oct;21 Suppl 7:vii134-9. doi: 10.1093/annonc/mdq374. Review.

PMID: 20943606

-----

63. [Clinical, molecular, and prognostic significance of WHO type inv\(3\)\(q21q26.2\)/t\(3;3\)\(q21;q26.2\) and various other 3q abnormalities in acute myeloid leukemia.](#)

Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppelle G, Vellenga E, van den Berg-de Ruyter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H.

-----

64. [Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 \(TRAIL-R1\), in patients with refractory colorectal cancer.](#)

Trarbach T, Moehler M, Heinemann V, Köhne CH, Przyborek M, Schulz C, Sneller V, Gallant G, Kanzler S.

Br J Cancer. 2010 Feb 2;102(3):506-12. doi: 10.1038/sj.bjc.6605507. Epub 2010 Jan 12.

PMID: 20068564 **Free PMC Article**

-----

65. [Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.](#)

Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczyński C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH.

Lancet Oncol. 2010 Jan;11(1):38-47. doi: 10.1016/S1470-2045(09)70330-4. Epub 2009 Nov 26.

PMID: 19942479

-----

66. [Clinical predictive factors.](#)

Köhne CH, Vanhoefer U, Hartung G.

Eur J Cancer. 2009 Sep;45 Suppl 1:43-9. doi: 10.1016/S0959-8049(09)70015-2. No abstract available.

PMID: 19775603

-----

67. [Accomplishments in 2008 in the adjuvant treatment of colon cancer.](#)

Marshall JL, de Gramont A, Köhne CH, Marshall JL, de Gramont A, Köhne CH.

Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S2-7.

PMID: 20011560 [PubMed] **Free PMC Article**

-----

68. [Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.](#)

Köhne CH, Lenz HJ.

Oncologist. 2009 May;14(5):478-88. doi: 10.1634/theoncologist.2008-0202. Epub 2009 May 1. Review.

PMID: 19411318 **Free Article**

-----

69. [Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.](#)

Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P, Tournigand C, Douillard JY, Stephens RJ, Grothey A, Goldberg RM.

J Clin Oncol. 2009 Apr 20;27(12):1948-55. doi: 10.1200/JCO.2008.20.2879. Epub 2009 Mar 2. Erratum in: J Clin Oncol. 2009 Jul 10;27(20):3410-1.

PMID: 19255311 **Free PMC Article**

-----

70. [Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.](#)

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P.

N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.

PMID: 19339720 **Free Article**

-----

71. [Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial.](#)

Huebner G, Link H, Kohne CH, Stahl M, Kretschmar A, Steinbach S, Folprecht G, Bernhard H, Al-Batran SE, Schoffski P, Burkart C, Kullmann F, Otremba B, Menges M, Hoffmann M, Kaiser U, Aldaoud A, Jahn A; German CUP Study Group.

Br J Cancer. 2009 Jan 13;100(1):44-9. doi: 10.1038/sj.bjc.6604818. Epub 2008 Dec 9.

PMID: 19066607 **Free PMC Article**

-----

72. [Treatment of the elderly colorectal cancer patient: SIOG expert recommendations.](#)

Papamichael D, Audisio R, Horiot JC, Glimelius B, Sastre J, Mitry E, Van Cutsem E, Gosney M, Köhne CH, Aapro M; SIOG.

Ann Oncol. 2009 Jan;20(1):5-16. doi: 10.1093/annonc/mdn532. Epub 2008 Oct 15. Review.

PMID: 18922882

-----

73. [Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.](#)

Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Köhne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Herrmann R; Central European Cooperative Oncology Group.

J Clin Oncol. 2008 Aug 1;26(22):3695-701. doi: 10.1200/JCO.2007.15.6240.

PMID: 18669454

-----

74. [Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.](#)

Köhne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Müller L, Janssens J, Bokemeyer C, Reimer P, Link H, Späth-Schwalbe E, Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E.

Ann Oncol. 2008 May;19(5):920-6. Epub 2007 Dec 6.

PMID: 18065406

-----

75. [Chemotherapy in elderly patients with colorectal cancer.](#)

Köhne CH, Folprecht G, Goldberg RM, Mitry E, Rougier P.

Oncologist. 2008 Apr;13(4):390-402. doi: 10.1634/theoncologist.2007-0043.

PMID: 18448553 **Free Article**

-----

76. [Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.](#)

Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E, Rougier P, Mitry E, Schubert U, Köhne CH.

J Clin Oncol. 2008 Mar 20;26(9):1443-51. doi: 10.1200/JCO.2007.14.0509.

PMID: 18349394

-----

77. [Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin \(FOLFIRI\) in first-line treatment of patients with metastatic colorectal cancer.](#)

Folprecht G, Tabernero J, Köhne CH, Zacharchuk C, Paz-Ares L, Rojo F, Quinn S, Casado E, Salazar R, Abbas R, Lejeune C, Marimón I, Andreu J, Ubbelohde U, Cortes-Funes H, Baselga J.

Clin Cancer Res. 2008 Jan 1;14(1):215-23. doi: 10.1158/1078-0432.CCR-07-1053.

PMID: 18172273 **Free Article**

-----

78. [Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer \(EORTC\)-gastrointestinal cancer group.](#)

Van Cutsem E, Van de Velde C, Roth A, Lordick F, Köhne CH, Cascinu S, Aapro M; European

Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.  
Eur J Cancer. 2008 Jan;44(2):182-94.  
PMID: 18093827

-----

79. [Treatment of advanced colorectal cancer in the elderly.](#)

Bruce C, Köhne CH, Audisio RA.

Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S84-7. Epub 2007 Nov 19. Review.

PMID: 18006266

-----

80. [Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification.](#)

Sorbye H, Köhne CH, Sargent DJ, Glimelius B.

Ann Oncol. 2007 Oct;18(10):1666-72. Epub 2007 Jul 28.

PMID: 17660495

-----

81. [Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.](#)

Nordlinger B, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulas V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G; European Colorectal Metastases Treatment Group.

Eur J Cancer. 2007 Sep;43(14):2037-45. Epub 2007 Sep 4. Review.

PMID: 17766104

-----

82. [Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.](#)

Punt CJ, Buyse M, Köhne CH, Hohenberger P, Labianca R, Schmoll HJ, Pählman L, Sobrero A, Douillard JY.

J Natl Cancer Inst. 2007 Jul 4;99(13):998-1003. Epub 2007 Jun 27. Review.

PMID: 17596575

-----

83. [Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.](#)

Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group.

J Clin Oncol. 2007 Jun 1;25(16):2212-7.

PMID: 17538165

-----

84. [Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks.](#)

Fensterer H, Radlwimmer B, Sträter J, Buchholz M, Aust DE, Julié C, Radvanyi F, Nordlinger B, Belluco C, Van Cutsem E, Köhne CH, Kestler HA, Schwaenen C, Nessling M, Lutz MP, Lichter P, Gress TM; EORTC Gastrointestinal (GI) Group.

BMC Cancer. 2007 Apr 2;7:58.

PMID: 17407575 **Free PMC Article**

-----

85. [Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial.](#)

Boeck S, Weigang-Köhler K, Fuchs M, Kettner E, Quietzsch D, Trojan J, Stötzer O, Zeuzem S, Lordick F, Köhne CH, Kröning H, Steinmetz T, Depenbrock H, Heinemann V.

Ann Oncol. 2007 Apr;18(4):745-51. Epub 2007 Jan 17.

PMID: 17229775

-----

86. [Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.](#)  
Folprecht G, Köhne CH, Lutz MP.  
Cancer Treat Res. 2007;134:425-40. Review. No abstract available.  
PMID: 17633071  
-----
87. [Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.](#)  
Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P;  
European Colorectal Metastases Treatment Group.  
Eur J Cancer. 2006 Sep;42(14):2212-21. Epub 2006 Aug 10. Review.  
PMID: 16904315  
-----
88. [Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal.](#)  
Köhne CH.  
Lancet Oncol. 2006 Jun;7(6):516-7. No abstract available.  
PMID: 16767832  
-----
89. [Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.](#)  
Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, Köhne CH.  
Ann Oncol. 2006 Mar;17(3):450-6. Epub 2005 Nov 22.  
PMID: 16303861  
-----
90. [Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.](#)  
Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M.  
Cancer Immunol Immunother. 2006 Mar;55(3):268-76. Epub 2005 Jul 21.  
PMID: 16034561  
-----
91. [On prejudice and facts and choices.](#)  
Köhne CH, Folprecht G.  
Ann Oncol. 2006 Feb;17(2):185-7. No abstract available.  
PMID: 16428244  
-----
92. [Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?](#)  
Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schöffski P, Schmoll H, Van Cutsem E, Köhne CH.  
Eur J Cancer. 2006 Jan;42(1):42-9. Epub 2005 Nov 18. Erratum in: Eur J Cancer. 2007 Feb;43(3):633.  
PMID: 16298522  
-----
93. [Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.](#)  
Folprecht G, Köhne CH.  
Nat Clin Pract Oncol. 2005 Nov;2(11):578-87. Review.  
PMID: 16270098  
-----

94. [Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.](#)  
Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH.  
Ann Oncol. 2005 Aug;16(8):1311-9. Epub 2005 May 3.  
PMID: 15870084  
-----
95. [Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.](#)  
Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, Lorenz M, Reichardt P, Rückle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler HG, Langenbuch T, Vanhoefer U, Rougier P, Voigtmann R, Müller L, Genicot B, Anak O, Nordlinger B; European Organisation for Research and Treatment of Cancer Gastrointestinal Group.  
J Clin Oncol. 2005 Aug 1;23(22):4856-65. Epub 2005 Jun 6.  
PMID: 15939923  
-----
96. [5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.](#)  
Steiner M, Seule M, Steiner B, Bauer I, Freund M, Köhne CH, Schuff-Werner P.  
J Clin Pathol. 2005 May;58(5):553-5.  
PMID: 15858133 **Free PMC Article**  
-----
97. [Never too old? Age should not be a barrier to enrollment in cancer clinical trials.](#)  
Aapro MS, Köhne CH, Cohen HJ, Extermann M.  
Oncologist. 2005 Mar;10(3):198-204. Review.  
PMID: 15793223 **Free Article**  
-----
98. [Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.](#)  
Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H, Köhne CH.  
Ann Oncol. 2004 Sep;15(9):1330-8.  
PMID: 15319237  
-----
99. [Role of new agents in the treatment of colorectal cancer.](#)  
Köhne CH, Bruce C, Folprecht G, Audisio R.  
Surg Oncol. 2004 Aug-Nov;13(2-3):75-81. Review.  
PMID: 15572089  
-----
100. [\[New therapy options in colorectal carcinoma\].](#)  
Folprecht G, Köhne CH.  
Ther Umsch. 2004 Jun;61(6):373-8. Review. German.  
PMID: 15253162  
-----
101. [Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations.](#)  
Schleyer E, Pursche S, Köhne CH, Schuler U, Renner U, Gschaidmeier H, Freiberg-Richter J, Leopold T, Jenke A, Bonin M, Bergemann T, le Coutre P, Gruner M, Bornhäuser M, Ottmann OG, Ehninger G.  
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 5;799(1):23-36.  
PMID: 14659433  
-----

102. [Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells.](#)  
Bornhäuser M, Illmer T, Le Coutre P, Pursche J, von Bonin M, Freiberg-Richter J, Schaich M, Platzbecker U, Thiede C, Ottmann OG, Köhne Ch, Braess J, Ehninger G, Schleyer E.  
Ann Hematol. 2004;83 Suppl 1:S61-4. Review.  
PMID: 15124675  
-----
103. [Current perspectives in the treatment of metastatic colorectal cancer.](#)  
Köhne CH, Folprecht G.  
Ann Oncol. 2004;15 Suppl 4:iv43-53. Review. No abstract available.  
PMID: 15477334  
-----
104. [\[Principles of postoperative therapy in rectal carcinoma\].](#)  
Folprecht G, Köhne CH.  
Chirurg. 2004 Jan;75(1):32-7. German.  
PMID: 14740125  
-----
105. [The role of new agents in the treatment of colorectal cancer.](#)  
Folprecht G, Köhne CH.  
Oncology. 2004;66(1):1-17. Review.  
PMID: 15031593  
-----
106. [Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.](#)  
Hartmann JT, Oechsle K, Quietzsch D, Wein A, Hofheinz RD, Honecker F, Nehls O, Köhne CH, Käfer G, Kanz L, Bokemeyer C.  
Br J Cancer. 2003 Dec 1;89(11):2051-6.  
PMID: 14647137 **Free PMC Article**  
-----
107. [\[Palliative therapy of colorectal cancer\].](#)  
Köhne CH.  
Onkologie. 2003 Dec;26 Suppl 7:41-7. Review. German.  
PMID: 14716142  
-----
108. [Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.](#)  
Köhne CH, Wils J, Lorenz M, Schöffski P, Voigtman R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Rückle H, Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ; European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.  
J Clin Oncol. 2003 Oct 15;21(20):3721-8. Epub 2003 Sep 8.  
PMID: 12963704  
-----
109. [Irinotecan is active in chemo-naïve patients with metastatic gastric cancer: a phase II multicentric trial.](#)  
Köhne CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips M, Preusser P, Knuth A, Clemens M, Bugat R, Figier I, Shani A, Fages B, Di Betta D, Jacques C, Wilke HJ.  
Br J Cancer. 2003 Sep 15;89(6):997-1001.  
PMID: 12966415 **Free PMC Article**  
-----

110. [Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment.](#)  
Kiani A, Köhne CH, Franz T, Passauer J, Haufe T, Gross P, Ehninger G, Schleyer E.  
Cancer Chemother Pharmacol. 2003 Mar;51(3):266-70. Epub 2003 Mar 4.  
PMID: 12655447  
-----
111. [Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.](#)  
Ducreux M, Köhne CH, Schwartz GK, Vanhoefer U.  
Ann Oncol. 2003;14 Suppl 2:ii17-23. Review.  
PMID: 12810453  
-----
112. [Colorectal cancer in the elderly: is palliative chemotherapy of value?](#)  
Honecker F, Köhne CH, Bokemeyer C.  
Drugs Aging. 2003;20(1):1-11. Review.  
PMID: 12513112  
-----
113. [Combined chemotherapy trials require combined pharmacogenetic approaches.](#)  
Steiner M, Schuff-Werner P, Freund M, Köhne CH.  
J Clin Oncol. 2002 Mar 1;20(5):1425-6. No abstract available.  
PMID: 11870191  
-----
114. [Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.](#)  
Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheel S, Hecker H.  
Ann Oncol. 2002 Feb;13(2):308-17.  
PMID: 11886010  
-----
115. [The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines.](#)  
Radetzki S, Köhne CH, von Haefen C, Gillissen B, Sturm I, Dörken B, Daniel PT.  
Oncogene. 2002 Jan 10;21(2):227-38.  
PMID: 11803466 **Free Article**  
-----
116. [\[Capsule instead of infusion--new oral chemotherapy option\].](#)  
Köhne CH.  
Krankenpfl J. 2002;40(1-2):42-3. German. No abstract available.  
PMID: 12035417  
-----
117. [Toxicity of irinotecan in patients with colorectal cancer.](#)  
Van Cutsem E, Douillard JY, Köhne CH.  
N Engl J Med. 2001 Nov 1;345(18):1351-2. No abstract available.  
PMID: 11794165 **Free Article**  
-----
118. [Chemotherapy in elderly patients with colorectal cancer.](#)  
Köhne CH, Grothey A, Bokemeyer C, Bontke N, Aapro M.  
Ann Oncol. 2001 Apr;12(4):435-42. Review.  
PMID: 11398873  
-----



119. [Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.](#)  
Thirion P, Piedbois P, Buyse M, O'Dwyer PJ, Cunningham D, Man A, Greco FA, Colucci G, Köhne CH, Di Constanzo F, Piga A, Palmeri S, Dufour P, Cassano A, Pajkos G, Pensel RA, Aykan NF, Marsh J, Seymour MT; Meta-Analysis Group in Cancer.  
Br J Cancer. 2001 Mar 2;84(5):611-20.  
PMID: 11237380 **Free PMC Article**  
-----
120. [Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas.](#)  
Lorenz M, Mueller HH, Mattes E, Gassel HJ, Junginger T, Saeger HD, Schramm H, Staib-Sebler E, Vetter G, Heinrich S, Köhne CH; German Cooperative Group on Liver Metastases (Arbeitsgruppe Lebermetastasen und -tumoren (ALM) in der Chirurgischen Arbeitsgemeinschaft Onkologie).  
Ann Oncol. 2001 Mar;12(3):321-5.  
PMID: 11332142  
-----
121. [High-dose etoposide phosphate and G-CSF mobilizes peripheral blood stem cells in patients that previously failed to mobilize.](#)  
Junghanss C, Leithäuser M, Wilhelm S, Kleine HD, Knopp A, Decker S, Alscher A, Casper J, Köhne CH, Freund M.  
Ann Hematol. 2001 Feb;80(2):96-102.  
PMID: 11261332  
-----
122. [Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.](#)  
Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, Köhne CH, Hillebrand T, Daniel PT, Fong Y, Lorenz M.  
Eur J Surg Oncol. 2001 Feb;27(1):80-7.  
PMID: 11237496  
-----
123. [Anatomical variations in the internal jugular veins of cancer patients affecting central venous access. Anatomical variation of the internal jugular vein.](#)  
Benter T, Teichgräber UK, Klühs L, Papadopoulos S, Köhne CH, Felix R, Dörken B.  
Ultraschall Med. 2001 Feb;22(1):23-6.  
PMID: 11253552  
-----
124. [Developments in the treatment of gastric cancer in Europe.](#)  
Köhne CH, Wils JA, Wilke HJ.  
Oncology (Williston Park). 2000 Dec;14(12 Suppl 14):22-5. Review.  
PMID: 11200144 **Free Article**  
-----
125. [UFT: mechanism of drug action.](#)  
Köhne CH, Peters GJ.  
Oncology (Williston Park). 2000 Oct;14(10 Suppl 9):13-8. Review.  
PMID: 11098484 **Free Article**  
-----
126. [Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer.](#)  
Kretschmar A, Reichardt P, Thuss-Patience PC, Hohenberger P, Benter T, Dörken B, Köhne CH.  
Oncology. 2000 Jun;59(1):14-7.  
PMID: 10895060  
-----

127. [Regional chemotherapy in the treatment of advanced pancreatic cancer--is it relevant?](#)  
Lorenz M, Heinrich S, Staib-Sebler E, Köhne CH, Wils J, Nordlinger B, Encke A.  
Eur J Cancer. 2000 May;36(8):957-65. Review.  
PMID: 10885598  
-----
128. [Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.](#)  
Armand JP, Cunningham D, van Cutsem E, Misset JL, Kohne CH.  
Anticancer Drugs. 1999 Nov;10 Suppl 1:S5-12. Review.  
PMID: 10630362  
-----
129. [Relevance of neoadjuvant and adjuvant treatment for patients with resectable liver metastases of colorectal carcinoma.](#)  
Lorenz M, Müller HH, Staib-Sebler E, Vetter G, Gog C, Petrowsky H, Köhne CH.  
Langenbecks Arch Surg. 1999 Aug;384(4):328-38. Review.  
PMID: 10473852  
-----
130. [Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases.](#)  
Sturm I, Köhne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dörken B, Daniel PT.  
J Clin Oncol. 1999 May;17(5):1364-74.  
PMID: 10334520  
-----
131. [Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.](#)  
Vanhoefler U, Harstrick A, Köhne CH, Achterrath W, Rustum YM, Seeber S, Wilke H.  
J Clin Oncol. 1999 Mar;17(3):907-13.  
PMID: 10071283  
-----
132. [Colorectal cancer liver metastasis: local treatment for a systemic disease?](#)  
Köhne CH, Lorenz M, Herrmann R.  
Ann Oncol. 1998 Sep;9(9):967-71. Review. No abstract available.  
PMID: 9818069  
-----
133. [Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.](#)  
Schöffski P, Freund M, Wunder R, Petersen D, Köhne CH, Hecker H, Schubert U, Ganser A.  
BMJ. 1998 Aug 8;317(7155):379-84.  
PMID: 9694753 **Free PMC Article**  
-----
134. [Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II study.](#)  
Hartmann JT, Köhne CH, Schmoll HJ, Daikeler T, Kanz L, Bokemeyer C.  
Oncology. 1998 Jul-Aug;55(4):320-5.  
PMID: 9663421  
-----
135. [Raltitrexed \(Tomudex\): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.](#)  
Köhne CH, Thuss-Patience P, Friedrich M, Daniel PT, Kretzschmar A, Benter T, Bauer B, Dietz R, Dörken B.  
Br J Cancer. 1998 Mar;77(6):973-7.

-----

136. [Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.](#)

Köhne CH, Schöffski P, Wilke H, Käufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U, Hecker H, Dörken B, Schmoll HJ.

J Clin Oncol. 1998 Feb;16(2):418-26.

PMID: 9469324

-----

137. [A pilot study on intensive weekly 24-hour intra-arterial infusion with 5-fluorouracil and folinic acid for colorectal liver metastases.](#)

Lorenz M, Staib-Sebler E, Gog C, Petrowsky H, Köhne CH, Encke A.

Oncology. 1998 Jan-Feb;55(1):53-8.

PMID: 9428376

-----

138. [Modulation of 5-fluorouracil with methotrexate and low-dose N-\(phosphonacetyl\)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.](#)

Köhne CH, Harstick A, Hiddemann W, Schöffski P, Wilke H, Bokemeyer C, Dörken B, Schmoll HJ.

Eur J Cancer. 1997 Oct;33(11):1896-9.

PMID: 9470854

-----

139. [\[Docetaxel in treatment of other solid tumors\].](#)

Kretschmar A, Köhne CH, Dörken B.

Med Klin (Munich). 1997 Sep 15;92 Suppl 4:16-22. Review. German.

PMID: 9446015

-----

140. [Modulation of 5-fluorouracil with methotrexate and low-dose N-\(phosphonacetyl\)-L-aspartate \(PALA\) is inactive in advanced pancreatic carcinoma.](#)

Harstick A, Köhne CH, Hiddemann W, Preusser P, Strumberg D, Berns T, Seeber S, Wilke H, Schmoll HJ.

Ann Oncol. 1997 Sep;8(9):917-8.

PMID: 9358946

-----

141. [\[After-care of colorectal carcinoma--value of tumor markers\].](#)

Köhne CH, Benter T.

Internist (Berl). 1997 Apr;38(4):363-5. German. No abstract available.

PMID: 9213578

-----

142. [Phase II evaluation of 5-fluorouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer.](#)

Köhne CH, Wilke H, Hiddemann W, Bokemeyer C, Lohrmann HP, Bodenstern H, Preiss J, Rauschecker H, Hill H, Käufer C, Fischer JT, Ohl U, Urbanitz D, Balleisen L, Schmoll HJ.

Oncology. 1997 Mar-Apr;54(2):96-101.

PMID: 9075778

-----

143. [The value of weekly high dose infusional 5-fluorouracil in the treatment of advanced colorectal cancer.](#)

Köhne CH, Daniel PT, Dörken B.

Tumori. 1997 Jan-Feb;83(1 Suppl):S56-60. No abstract available.

PMID: 9154070

- 
144. [Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases?](#)  
Cohen AM, Kemeny NE, Köhne CH, Wils J, de Takats PG, Kerr DJ.  
Eur J Cancer. 1996 Dec;32A(13):2195-205. Review.  
PMID: 9038600
- 
145. [\[Risk of secondary neoplasia after treatment of malignant germ cell tumors of the testis\].](#)  
Bokemeyer C, Kuczyk MA, Köhne CH, Haupt A, Schmoll HJ.  
Med Klin (Munich). 1996 Nov 15;91(11):703-10. Review. German. No abstract available.  
PMID: 9036294
- 
146. [The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.](#)  
Köhne CH, Wilke H, Schöffski P, Schmoll HJ.  
J Infus Chemother. 1996 Fall;6(4):206-10. Review. No abstract available.  
PMID: 9229317
- 
147. [\[Progress in development of chemotherapy of colorectal carcinoma\].](#)  
Köhne CH.  
Med Klin (Munich). 1996 Apr 12;91 Suppl 3:33-7. German.  
PMID: 8692117
- 
148. [Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society \(AIO\).](#)  
Köhne CH, Wilke H, Hecker H, Schöffski P, Käufer C, Rauschecker H, Andreesen R, Ohl U, Lange HJ, Klaassen U, et al.  
Ann Oncol. 1995 May;6(5):461-6.  
PMID: 7669711
- 
149. [Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.](#)  
Köhne CH, Hiddemann W, Schüller J, Weiss J, Lohrmann HP, Schmitz-Hübner U, Bodenstern H, Schöber C, Wilke H, Grem J, et al.  
J Clin Oncol. 1995 May;13(5):1201-8.  
PMID: 7738622